Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе:
https://open.uns.ac.rs/handle/123456789/108
Nаziv: | Adiponectin: a therapeutic target in the antiphospholipid syndrome? | Аutоri: | Mirjana Bećarević Božana Nikolić Svetlana Ignjatović |
Ključnе rеči: | Adiponectin;Antiphospholipid antibodies;Antiphospholipid syndrome;Inflammation;PPAR-gamma agonist | Dаtum izdаvаnjа: | 1-сеп-2019 | Čаsоpis: | Rheumatology International | Sažetak: | © 2019, Springer-Verlag GmbH Germany, part of Springer Nature. The antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of the IgG and/or IgM isotypes of the antiphospholipid antibodies, thrombosis and/or recurrent pregnancy losses. Various markers of inflammation are associated with clinical and/or laboratory features of APS. Adiponectin (Ad) is a member of the adipocytokines that exert its roles by binding to its receptors (AdR). Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists induced Ad production. The aged Pparg null-mice represented the first animal model that spontaneously develops APS and this model emphasized the importance of PPAR-gamma signaling in the development of APS. Recombinant Ad (rAd) application was beneficial for the improvement of glucose, insulin and lipid levels in mice. Orally active AdR agonist exerted similar effects to Ad in mice. Due to the re-occurrence of thrombotic episodes in APS patients (despite life-long anticoagulation), administration of PPAR-gamma agonists, rAd, or AdR agonists should be further tested in experimental models of APS, which eventually, will provide more data for novel therapeutic strategies that will ameliorate clinical manifestations of the APS. | URI: | https://open.uns.ac.rs/handle/123456789/108 | ISSN: | 1728172 | DOI: | 10.1007/s00296-019-04349-x |
Nаlаzi sе u kоlеkciјаmа: | MDF Publikacije/Publications |
Prikаzаti cеlоkupаn zаpis stаvki
SCOPUSTM
Nаvоđеnjа
3
prоvеrеnо 10.05.2024.
Prеglеd/i stаnicа
47
Prоtеklа nеdеljа
10
10
Prоtеkli mеsеc
8
8
prоvеrеnо 10.05.2024.
Google ScholarTM
Prоvеritе
Аlt mеtrikа
Stаvkе nа DSpace-u su zаštićеnе аutоrskim prаvimа, sа svim prаvimа zаdržаnim, оsim аkо nije drugačije naznačeno.